Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease

Summary

Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease, with many of those being young children and adolescents. Physicians need better ways to inform decisions on treatment. The main reason for this research study is to determine if a computer program that formulates a dose based on a patient's blood testing results can better achieve the optimal drug level as compared to standard dosing.

Timeline

Start

2021-10-01

Primary completion

2024-08-01

Completion

2024-08-01

Drugs

Indications